This Master Rollover Study includes sub-protocols with different study drugs. This Master Rollover Protocol describes core study elements that are applicable to all study drugs that will be provided under the Rollover Study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent form, prior to the start of any study-specific qualification procedures and willing to comply with all study requirements.
Currently enrolled in a DS or DS/AZ-sponsored parent study that has met EOS definition.
No evidence of progressive disease and determined to have investigator-assessed clinical benefit from continued treatment with a DS or DS/AZ alliance study drug(s).
You may not be if
Participants with any unresolved/ongoing AE(s) that meets the study drug discontinuation criteria
Participant who has been off T-DXd therapy for \>18 weeks (126 days) between the last dose from the parent study and the initiation of study drug administration on this study
Clareo Health | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
